JWH-210 is an analgesic chemical from the naphthoylindole family, which acts as a potent cannabinoid agonist at both the CB1 and CB2 receptors. JWH-210 is one of the most potent 4-substituted naphthoyl derivatives in the naphthoylindole series, having a higher binding affinity. The physiological and toxicological properties of this compound have not been evaluated in humans.

JWH-018 is a full agonist synthetic cannabinoid with a high binding affinity to CB1 and CB2 cannabinoid receptors. JWH-018 has not been used in therapy. Many of the risks linked to cannabis use are also present in the case of JWH-018, among them complications in patients suffering from cardiovascular diseases and triggering of acute psychosis. JWH-018 has not been used in therapy. Studies in mice showed anti-inflammatory and cancer chemopreventive properties of JWH-018.

EAM-2201 acts as a full agonist with of cannabinoid receptors, CB1 and CB2. This compound was first identified in Japan in 2012 as an ingredient in synthetic cannabis smoking blends and belongs to narcotic substances, that is why was banned in some countries.